277 related articles for article (PubMed ID: 23977065)
1. Heterosubtypic antiviral activity of hemagglutinin-specific antibodies induced by intranasal immunization with inactivated influenza viruses in mice.
Muramatsu M; Yoshida R; Miyamoto H; Tomabechi D; Kajihara M; Maruyama J; Kimura T; Manzoor R; Ito K; Takada A
PLoS One; 2013; 8(8):e71534. PubMed ID: 23977065
[TBL] [Abstract][Full Text] [Related]
2. Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.
Okuya K; Yoshida R; Manzoor R; Saito S; Suzuki T; Sasaki M; Saito T; Kida Y; Mori-Kajihara A; Kondoh T; Sato M; Kajihara M; Miyamoto H; Ichii O; Higashi H; Takada A
J Virol; 2020 Jun; 94(12):. PubMed ID: 32269119
[TBL] [Abstract][Full Text] [Related]
3. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses.
Yoshida R; Igarashi M; Ozaki H; Kishida N; Tomabechi D; Kida H; Ito K; Takada A
PLoS Pathog; 2009 Mar; 5(3):e1000350. PubMed ID: 19300497
[TBL] [Abstract][Full Text] [Related]
4. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
J Virol; 2017 May; 91(9):. PubMed ID: 28179535
[TBL] [Abstract][Full Text] [Related]
5. Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity.
Muramatsu M; Yoshida R; Yokoyama A; Miyamoto H; Kajihara M; Maruyama J; Nao N; Manzoor R; Takada A
PLoS One; 2014; 9(1):e85582. PubMed ID: 24465606
[TBL] [Abstract][Full Text] [Related]
6. Intranasal immunization of baculovirus displayed hemagglutinin confers complete protection against mouse adapted highly pathogenic H7N7 reassortant influenza virus.
Rajesh Kumar S; Syed Khader SM; Kiener TK; Szyporta M; Kwang J
PLoS One; 2013; 8(6):e63856. PubMed ID: 23762234
[TBL] [Abstract][Full Text] [Related]
7. Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies.
Goff PH; Eggink D; Seibert CW; Hai R; Martínez-Gil L; Krammer F; Palese P
PLoS One; 2013; 8(11):e79194. PubMed ID: 24223176
[TBL] [Abstract][Full Text] [Related]
8. Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins.
Marjuki H; Mishin VP; Chai N; Tan MW; Newton EM; Tegeris J; Erlandson K; Willis M; Jones J; Davis T; Stevens J; Gubareva LV
J Virol; 2016 Dec; 90(23):10446-10458. PubMed ID: 27630240
[TBL] [Abstract][Full Text] [Related]
9. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
[TBL] [Abstract][Full Text] [Related]
10. H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model.
Carreño JM; Strohmeier S; Kirkpatrick Roubidoux E; Hai R; Palese P; Krammer F
mBio; 2020 Dec; 11(6):. PubMed ID: 33323511
[TBL] [Abstract][Full Text] [Related]
11. Hemagglutinin stalk-based monoclonal antibody elicits broadly reactivity against group 1 influenza A virus.
Huang J; Huang N; Fan M; Zhao L; Luo Y; Ding P; Tian M; Liu Q; Guo Y; Zhao J; Zheng Y; Zhang H; Ping J
Virol J; 2020 Dec; 17(1):191. PubMed ID: 33287849
[TBL] [Abstract][Full Text] [Related]
12. Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice.
van der Lubbe JEM; Verspuij JWA; Huizingh J; Schmit-Tillemans SPR; Tolboom JTBM; Dekking LEHA; Kwaks T; Brandenburg B; Meijberg W; Zahn RC; Roozendaal R; Kuipers H
Front Immunol; 2018; 9():2350. PubMed ID: 30369928
[TBL] [Abstract][Full Text] [Related]
13. Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase.
Yoshikawa T; Suzuki Y; Nomoto A; Sata T; Kurata T; Tamura Si
Vaccine; 2002 Nov; 21(1-2):60-6. PubMed ID: 12443663
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatics design and experimental validation of influenza A virus multi-epitopes that induce neutralizing antibodies.
Ramírez-Salinas GL; García-Machorro J; Rojas-Hernández S; Campos-Rodríguez R; de Oca AC; Gomez MM; Luciano R; Zimic M; Correa-Basurto J
Arch Virol; 2020 Apr; 165(4):891-911. PubMed ID: 32060794
[TBL] [Abstract][Full Text] [Related]
15. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
16. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules.
Tamura S; Funato H; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T
Eur J Immunol; 1991 Jun; 21(6):1337-44. PubMed ID: 1646112
[TBL] [Abstract][Full Text] [Related]
17. The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.
Kawai A; Yamamoto Y; Nogimori T; Takeshita K; Yamamoto T; Yoshioka Y
J Virol; 2021 Sep; 95(20):e0118021. PubMed ID: 34379511
[TBL] [Abstract][Full Text] [Related]
18. Heterosubtypic antibodies to influenza A virus have limited activity against cell-bound virus but are not impaired by strain-specific serum antibodies.
Wyrzucki A; Bianchi M; Kohler I; Steck M; Hangartner L
J Virol; 2015 Mar; 89(6):3136-44. PubMed ID: 25552718
[TBL] [Abstract][Full Text] [Related]
19. Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus.
Ding H; Tsai C; Zhou F; Buchy P; Deubel V; Zhou P
PLoS One; 2011 Mar; 6(3):e17821. PubMed ID: 21464977
[TBL] [Abstract][Full Text] [Related]
20. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
